Key Points
- AtriCure director Maggie Yuen sold 3,500 shares at an average price of $38.42, generating $134,470. The sale reduced her direct holdings by nearly 20% to 14,015 shares.
- AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding the $151.8 million analyst revenue estimate. Shares opened at $41.39 after rising 4.8%.
- Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $48.50 target price; institutional investors own 99.11% of the company.
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) Director Maggie Yuen sold 3,500 shares of the company's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the completion of the sale, the director directly owned 14,015 shares in the company, valued at approximately $538,456.30. The trade was a 19.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
AtriCure Trading Up 4.8%
Shares of AtriCure stock opened at $41.39 on Friday. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $43.18. The stock has a market capitalization of $2.11 billion, a P/E ratio of 197.10 and a beta of 1.20. The company has a 50-day simple moving average of $32.25 and a 200 day simple moving average of $31.38. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.
AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the previous year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. acquired a new position in AtriCure during the 2nd quarter worth $37,000. Harbor Investment Advisory LLC acquired a new stake in shares of AtriCure in the 2nd quarter valued at $40,000. Smartleaf Asset Management LLC increased its stake in shares of AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock valued at $46,000 after buying an additional 429 shares during the period. Fifth Third Bancorp bought a new stake in shares of AtriCure during the first quarter worth $51,000. Finally, Global Retirement Partners LLC bought a new stake in shares of AtriCure during the second quarter worth $52,000. Institutional investors own 99.11% of the company's stock.
Analysts Set New Price Targets
ATRC has been the topic of several recent analyst reports. Zacks Research raised AtriCure from a "hold" rating to a "strong-buy" rating in a report on Friday, July 24th. Canaccord Genuity Group raised their price target on AtriCure from $53.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday, May 6th. UBS Group cut their price objective on AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research report on Tuesday, July 28th. Wall Street Zen lowered AtriCure from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 2nd. Finally, Citigroup restated a "market outperform" rating on shares of AtriCure in a report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $48.50.
Get Our Latest Stock Report on AtriCure
About AtriCure
(
Get Free Report)
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
